Shuo Ma, MD, PhD

Articles

Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D

Shuo Ma, MD, PhD

July 15th 2024

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

Dr. Ma on Utilizing Zanabrutinib in CLL

Shuo Ma, MD, PhD

May 10th 2022

Shuo Ma, MD, PhD, discusses the utilization of zanubrutinib in chronic lymphocytic leukemia.

Dr. Ma on Developing Novel Agents in BTK Inhibitor–Resistant CLL

Shuo Ma, MD, PhD

October 15th 2020

Shuo Ma, MD, PhD, discusses the need to develop novel agents to treat patients with chronic lymphocytic leukemia who develop resistance to BTK inhibitors.

$Dr. Ma on the Utility of BTK Inhibitors in Relapsed/Refractory CLL$

Dr. Ma on the Utility of BTK Inhibitors in Relapsed/Refractory CLL

Shuo Ma, MD, PhD

September 24th 2020

Shuo Ma, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory chronic lymphocytic leukemia.

Dr. Ma on First- and Second-Generation BTK Inhibitors in B-Cell Malignancies

Shuo Ma, MD, PhD

September 9th 2020

Shuo Ma, MD, PhD, highlights ongoing research with BTK inhibitors in B-cell malignancies.

Dr. Shuo Ma on Non-Chemotherapy Regimens for Hematologic Malignancies

Shuo Ma, MD, PhD

February 20th 2015

Shuo Ma, MD, PhD, assistant professor at Northwestern University in the Robert H. Lurie Comprehensive Cancer Center discusses advances in non-chemotherapy regimens for patients with hematologic malignancies.